NEW
YORK, Aug. 12, 2022 /PRNewswire/ --
Synaptogenix, Inc. (Nasdaq: SNPX) ("the Company"), a clinical-stage
biopharmaceutical company developing regenerative therapeutics for
neurodegenerative disorders, today announced that Dr. Daniel L. Alkon , the Company's President and
Chief Scientific Officer, will appear as a featured guest on TD
Ameritrade Network's "Trading 360" today, Friday, August 12, 2022 at 10:30am Eastern time
(www.TDameritradenetwork.com).
Dr. Alkon will discuss the progression of treatments for
Alzheimer's disease ("AD"), Synaptogenix's lead drug, Bryostatin-1,
and its ongoing National Institutes of Health ("NIH") sponsored,
Phase 2b clinical trial of
Bryostatin-1 for patients suffering from advanced and moderately
severe AD.
"Trading 360" with Nicole Petallides features Wall
Street's best traders, analysts and technicians to break down
sectors and stocks moving markets. "Trading 360" with
Nicole Petallides focuses on
disruptive companies and new technologies driving
market headlines while providing investors a 360-degree
actionable approach to trading.
About Synaptogenix, Inc.
Synaptogenix is a clinical-stage biopharmaceutical company that
has historically worked to develop novel therapies for
neurodegenerative diseases. Synaptogenix has conducted clinical and
preclinical studies of its lead therapeutic candidate,
Bryostatin-1, in AD. Preclinical studies have also demonstrated
Bryostatin's regenerative mechanisms of action for the rare
disease, Fragile X syndrome, and for other neurodegenerative
disorders such as multiple sclerosis, stroke, and traumatic brain
injury. The U.S. Food and Drug Administration has granted Orphan
Drug Designation to Synaptogenix for Bryostatin-1 as a treatment
for Fragile X syndrome. Bryostatin-1 has already undergone testing
in more than 1,500 people in cancer studies, thus creating a large
safety data base that will further inform clinical trial
designs.
Additional information about Synaptogenix, Inc. may be found on
its website: www.synaptogen.com.
Forward-Looking
Statements
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking
statements. These forward-looking statements include statements
regarding the anticipated initiation of a clinical trial to treat
Multiple Sclerosis with Bryostatin and continued development
of use of Bryostatin-1 for AD, Fragile X and other cognitive
diseases. Such forward-looking statements are subject to risks and
uncertainties and other influences, many of which the Company has
no control over. There can be no assurance that the clinical
program for Bryostatin-1 will be successful in demonstrating safety
and/or efficacy, that we will not encounter problems or delays in
clinical development, or that Bryostatin-1 will ever receive
regulatory approval or be successfully commercialized. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Additional
factors that may influence or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing,
the significant length of time associated with drug development and
related insufficient cash flows and resulting illiquidity, the
Company's patent portfolio, the Company's inability to expand its
business, significant government regulation of pharmaceuticals and
the healthcare industry, lack of product diversification,
availability of the Company's raw materials, existing or increased
competition, stock volatility and illiquidity, and the Company's
failure to implement its business plans or strategies. These and
other factors are identified and described in more detail in the
Company's filings with the Securities and Exchange Commission. The
Company does not undertake to update these forward-looking
statements.
Contact Information:
Investors and Media
800-811-5591
ir@synaptogen.com
Robert Weinstein
Chief Financial Officer
Synaptogenix, Inc.
rweinstein@synaptogen.com
View original
content:https://www.prnewswire.com/news-releases/synaptogenix-announces-live-appearance-of-its-president-and-cso-on-streaming-financial-news-network-301604803.html
SOURCE Synaptogenix, Inc.